Global drugmakers eye more China biotech deals after record year
Health Care
Executives want ‘skin in the game’ despite signs of stock market cooldown
Technicians work at Zhejiang Youlai Biotechnology Co. in Hangzhou on April 16. China’s pharmaceutical sector is attracting global interest. © AP
WATARU SUZUKI and LORRETTA CHEN
SHANGHAI/HONG KONG — Global pharmaceutical executives are hungry for more deals with Chinese biotech companies after a record year, even as a stock market boom shows signs of cooling down.
